For Patients &
Things to Know about Wet AMD
- Wet AMD is a progressive disease that affects the macula, the region of the retina at the back of the eye responsible for central vision.
- Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with this condition.i
- The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age.i,ii
- AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.ii
Reasons a New Therapy is Needed for Vision-Threatening Eye Diseases like Wet AMD
- Although the current standard of care – ocular injections of anti-VEGF agents to inhibit the growth of blood vessels and prevent fluid leakage – is effective in the short-term, it requires visits to the doctor every 4-12 weeks for more injections.
- Complying with this regimen can be difficult for patients and their caregivers – patients have reported that average therapy visits can require as much as 12 hours of their time.iii
- As a result, many patients skip or discontinue scheduled treatments, which leads to underdosing that can cause loss of vision.
- Retina specialists report that decreasing the frequency of injections is by far the largest unmet need for wet AMD patients.iv
- Studies of anti-VEGF treatments suggest that gains in visual acuity were largely lost in two-thirds of patients who were followed for more than 7 years.v
i Bright Focus Foundation. Age-Related Macular Degeneration: Facts & Figures. [Internet; cited October 2021]. Available from https://www.brightfocus.org/macular/article/age-related-macular-facts-figures.
ii Wong WL, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:106–16.
iii American Macular Degeneration Foundation (AMDF) Website. Accessed on 18 December 2020 at https://www.macular.org/what-macular-degeneration.
iv Scott AW, Bressler MN, Ffolkes S, Wittenborn JS, Jorkasky J. Public attitudes about eye and vision health. JAMA Ophthalmology. 2016;132(10):1111-1118.
v ADVM third-party market research.